Skip to main content
    T

    Theravance Biopharma Inc (TBPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $17.03
    +0.00 (+0.00%)

    Market Cap: $884.18M

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Theravance Biopharma Inc (TBPH) Financials: Revenue, Profit and Cash Flow

    Updated Aug 10, 2026. Financial statements from company filings, amounts in US dollars.

    Theravance Biopharma reported revenue of $107.46M for the fiscal year ended Dec 31, 2025, up 66.9% from the year before. That year, net income was $105.89M with a net margin of 98.5%, operating cash flow was $238.54M and free cash flow was $238.50M. The quarter ended Jun 30, 2026 had revenue of $20.73M and net income of -$5.90M.

    Revenue and Margins

    The operating margin was -3.4% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $48.65M, a compound annual rate of 9.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$107.46M+66.9%100.0%-3.4%98.5%
    Dec 2024$64.38M+12.1%100.0%-72.9%-87.6%
    Dec 2023$57.42M+11.8%100.0%-97.6%-96.1%
    Dec 2022$51.35M-7.2%100.0%-179.1%1698.5%
    Dec 2021$55.31M-23.0%100.0%-466.1%-360.6%
    Dec 2020$71.86M-2.1%100.0%-414.2%-386.9%
    Dec 2019$73.41M+21.6%100.0%-343.1%-322.1%
    Dec 2018$60.37M+292.4%98.8%-395.5%-357.0%
    Dec 2017$15.39M-68.4%60.8%-1690.6%-1855.0%
    Dec 2016$48.65MN/A94.1%-371.0%-391.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$107.46M$64.38M$57.42M$51.35M$55.31M$71.86M$73.41M$60.37M$15.39M$48.65M
    Cost of revenue$0$0$0$0$0$0$0$715.00K$6.03M$2.89M
    Gross profit$107.46M$64.38M$57.42M$51.35M$55.31M$71.86M$73.41M$59.66M$9.36M$45.75M
    Research and development$37.41M$37.64M$40.62M$63.39M$193.66M$260.95M$219.25M$201.35M$173.89M$141.71M
    Operating income-$3.60M-$46.95M-$56.03M-$91.96M-$257.78M-$297.63M-$251.91M-$238.75M-$260.12M-$180.47M
    Net income$105.89M-$56.42M-$55.19M$872.13M-$199.43M-$278.02M-$236.46M-$215.52M-$285.40M-$190.67M
    EBITDA$84.52M-$38.45M-$42.66M-$75.71M-$248.09M-$286.75M-$237.31M-$222.30M-$251.53M-$176.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Gross profit$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Operating income-$8.28M-$9.48M$20.01M-$6.46M-$2.73M-$14.43M-$9.20M-$10.84M-$15.71M-$11.21M-$6.24M-$8.76M
    Net income-$5.90M-$4.93M$61.02M$3.62M$54.84M-$13.58M-$15.53M-$12.70M-$16.53M-$11.66M-$8.51M-$8.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $10.95M by $156.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$485.57M$354.16M$382.00M$607.40M$374.82M$469.06M$408.83M$560.24M$441.40M$639.25M
    Current assets$418.46M$161.07M$133.54M$353.46M$249.87M$393.34M$338.49M$532.82M$378.75M$528.50M
    Cash and equivalents$167.81M$37.80M$39.55M$298.17M$89.96M$81.47M$58.06M$378.02M$88.98M$344.71M
    Total liabilities$188.85M$178.62M$169.00M$165.60M$713.39M$772.81M$632.67M$611.82M$326.22M$289.02M
    Short-term debt$10.95M$10.71M$3.92M$6.75M$16.94M$19.33M$9.85MN/A$223.75M$222.68M
    Long-term debtN/AN/AN/AN/A$228.03M$226.96M$225.89M$224.82M$223.75M$222.68M
    Shareholder equity$296.72M$175.54M$213.00M$441.80M-$338.57M-$303.75M-$223.84M-$51.59M$115.18M$350.23M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$469.77M$472.31M$485.57M$415.46M$426.04M$343.58M$354.16M$356.11M$362.03M$371.31M$382.00M$413.59M
    Total liabilities$180.06M$181.72M$188.85M$182.78M$201.19M$177.60M$178.62M$170.45M$168.34M$166.44M$169.00M$167.46M
    Cash and equivalents$219.77M$288.10M$167.81M$174.77M$281.93M$110.61M$37.80M$23.38M$46.34M$53.84M$39.55M$71.69M
    Shareholder equity$289.70M$290.59M$296.72M$232.68M$224.85M$165.98M$175.54M$185.65M$193.69M$204.87M$213.00M$246.13M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$238.54M-$11.54M-$27.00M-$186.99M-$207.86M-$250.40M-$238.20M-$112.87M-$201.05M-$98.99M
    Capital expenditures$42.00K$332.00K$2.49M$572.00K$3.41M$6.62M$3.18M$7.24M$2.41M$2.13M
    Free cash flow$238.50M-$11.87M-$29.48M-$187.56M-$211.26M-$257.02M-$241.37M-$120.11M-$203.46M-$101.12M
    Dividends paidN/AN/AN/A$802.00KN/A$385.06MN/AN/A$0$0
    Share repurchases$0$445.00K$197.05M$128.83M$0$0N/AN/AN/AN/A
    Investing cash flow-$105.28M$12.28M-$32.70M$1.15B$124.49M$10.72M-$83.05M$176.71M-$56.33M-$148.24M
    Financing cash flow-$3.25M-$2.50M-$198.93M-$758.81M$91.86M$263.08M$1.29M$225.20M$1.66M$479.23M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$6.96M$73.28M-$6.06M-$6.51M$208.07M$43.04M-$902.00K-$5.20M-$4.42M-$1.02M-$854.00K-$2.49M
    Capital expendituresN/A$0$8.00K$0$34.00K$0$190.00K$15.00K$36.00K$91.00K$677.00K$21.00K
    Free cash flowN/A$73.28M-$6.07M-$6.51M$208.04M$43.04M-$1.09M-$5.21M-$4.45M-$1.11M-$1.53M-$2.51M
    Last 12 quarters

    Frequently Asked Questions About TBPH

    What is Theravance Biopharma's annual revenue?

    Theravance Biopharma reported revenue of $107.46M for the fiscal year ended Dec 31, 2025.

    How fast is Theravance Biopharma's revenue growing?

    Revenue was up 66.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 27.9%.

    Is Theravance Biopharma profitable?

    Yes. Theravance Biopharma reported net income of $105.89M for the fiscal year ended Dec 31, 2025, with a net margin of 98.5%.

    How much free cash flow does TBPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $238.54M minus capital expenditures of $42.00K produced free cash flow of $238.50M.

    How much debt does Theravance Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $10.95M and cash and equivalents of $167.81M.